Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Clinical practice decisions in endocrine therapy.

Untch M, Thomssen C.

Cancer Invest. 2010;28 Suppl 1:4-13. doi: 10.3109/07357907.2010.501637. Review.

PMID:
20653403
2.
3.

Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.

Chlebowski RT.

Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:25-34. doi: 10.1007/s10549-008-0237-5. Epub 2008 Dec 20.

PMID:
19101792
4.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
5.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.

PMID:
16098456
6.

Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.

Spicer J, Ellis P.

Cancer Lett. 2007 Apr 18;248(2):165-74. Epub 2006 Aug 21. Review.

PMID:
16919870
7.

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.

J Natl Compr Canc Netw. 2006 Nov;4(10):971-9. Review.

PMID:
17112447
8.

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

Kaufmann M, Rody A.

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. Epub 2006 Apr 18. Review.

PMID:
16621229
9.

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.

van de Velde CJ, Verma S, van Nes JG, Masterman C, Pritchard KI.

Cancer Treat Rev. 2010 Feb;36(1):54-62. doi: 10.1016/j.ctrv.2009.10.003. Epub 2009 Nov 26. Review.

PMID:
19944537
10.

Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.

Goss PE.

Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12.

PMID:
16730271
11.

Are aromatase inhibitors superior to antiestrogens?

Howell A, Buzdar A.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):237-47. Review.

PMID:
15860266
12.

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL.

J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71.

PMID:
16145047
13.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, R├╝cklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
14.
15.

Emerging role of aromatase inhibitors in the adjuvant setting.

Goss PE.

Am J Clin Oncol. 2003 Aug;26(4):S27-33. Review.

PMID:
12902874
16.

Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.

Dodwell D, Williamson D.

Cancer Treat Rev. 2008 Apr;34(2):137-44. Epub 2007 Nov 14. Review.

PMID:
18006236
17.

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.

Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.

PMID:
16870082
18.

Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.

Colozza M, Califano R, Minenza E, Dinh P, Azambuja E.

Mini Rev Med Chem. 2008 Jun;8(6):564-74. Review.

PMID:
18537711
19.

Early recurrence risk: aromatase inhibitors versus tamoxifen.

Bria E, Carlini P, Cuppone F, Vaccaro V, Milella M, Cognetti F.

Expert Rev Anticancer Ther. 2010 Aug;10(8):1239-53. doi: 10.1586/era.10.54. Review.

PMID:
20735310
20.

Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?

Tang SC.

Cancer Invest. 2008 Jun;26(5):481-90. doi: 10.1080/07357900701781812. Review.

PMID:
18568770

Supplemental Content

Support Center